生物制品的市场独占权。 - Suppr

Market exclusivity for biologics.

作者信息

Wheadon David E

出版信息

N Engl J Med. 2010 Feb 18;362(7):661; author reply 661-2. doi: 10.1056/NEJMc0912463.

DOI:10.1056/NEJMc0912463

PMID:20164494

Abstract

摘要

相似文献

Market exclusivity for biologics.

N Engl J Med. 2010 Feb 18;362(7):661; author reply 661-2. doi: 10.1056/NEJMc0912463.

Balancing innovation, access, and profits--market exclusivity for biologics.

N Engl J Med. 2009 Nov 12;361(20):1917-9. doi: 10.1056/NEJMp0908496. Epub 2009 Oct 14.

Potential pathways for abbreviated approval of generic biologics under existing law and proposed reforms to the law.

Food Drug Law J. 2007;62(1):77-137.

Balancing US patent and FDA approval processes: strategically optimizing market exclusivity.

Drug Discov Today. 2004 Jun 15;9(12):509-12. doi: 10.1016/S1359-6446(04)03067-3.

SuperGenerics: a better alternative for biogenerics.

Drug Discov Today. 2005 Apr 15;10(8):533-5. doi: 10.1016/S1359-6446(05)03410-0.

Informed by the European Union experience: what the United States can anticipate and learn from the European Union's regulatory approach to biosimilars.

Seton Hall Law Rev. 2011;41(2):559-92.

Policy on 180-day marketing exclusivity for drugs marketed under abbreviated new drug applications; clarification--FDA. Clarification.

Fed Regist. 1997 Nov 28;62(229):63268-9.

Market watch: Sales of biologics to show robust growth through to 2013.

Nat Rev Drug Discov. 2009 Nov;8(11):837. doi: 10.1038/nrd3040.

Bills target biosimilar drugs.

Nature. 2009 Mar 26;458(7237):394-5. doi: 10.1038/458394b.

Intellectual property law in Israel, and US and European objections: Market exclusivity vs. data exclusivity.

Nat Biotechnol. 2004 Dec;22(12):1591-2. doi: 10.1038/nbt1204-1591.

引用本文的文献

Cost-effectiveness of proton beam therapy for intraocular melanoma.

PLoS One. 2015 May 18;10(5):e0127814. doi: 10.1371/journal.pone.0127814. eCollection 2015.

Unintended effects of orphan product designation for rare neurological diseases.

Ann Neurol. 2012 Oct;72(4):481-90. doi: 10.1002/ana.23672.

An empirical review of major legislation affecting drug development: past experiences, effects, and unintended consequences.

Milbank Q. 2011 Sep;89(3):450-502. doi: 10.1111/j.1468-0009.2011.00636.x.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Market exclusivity for biologics.

作者信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献